Search Results - "OSBORNE, RANDY" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Haswell: The Fourth-Generation Intel Core Processor

Haswell: The Fourth-Generation Intel Core Processor

by Hammarlund, Per, Martinez, Alberto J., Bajwa, Atiq A., Hill, David L., Hallnor, Erik, Jiang, Hong, Dixon, Martin, Derr, Michael, Hunsaker, Mikal, Kumar, Rajesh, Osborne, Randy B., Rajwar, Ravi, Singhal, Ronak, D'Sa, Reynold, Chappell, Robert, Kaushik, Shiv, Chennupaty, Srinivas, Jourdan, Stephan, Gunther, Steve, Piazza, Tom, Burton, Ted
Published in IEEE MICRO (01.03.2014)

Get full text

Journal Article

Optimized GNSS cal/val site selection for expanding InSAR viability in areas with low phase coherence: A case study for southern Louisiana

Optimized GNSS cal/val site selection for expanding InSAR viability in areas with low phase coherence: A case study for southern Louisiana

by Varugu, Bhuvan K., Jones, Cathleen E., Wang, Ke, Chen, Jingyi, Osborne, Randy L., Voyiadjis, George Z.
Published in IEEE journal of selected topics in applied earth observations and remote sensing (01.01.2024)

Get full text

Journal Article

First novel anti-tuberculosis drug in 40 years

First novel anti-tuberculosis drug in 40 years

by Osborne, Randy
Published in Nature biotechnology (01.02.2013)

Get full text

Journal Article

Fresh from the biotech pipeline--2012

Fresh from the biotech pipeline--2012

by Osborne, Randy
Published in Nature biotechnology (01.02.2013)

Get full text

Journal Article

First-in-class insomnia drug on the brink of approval nod

First-in-class insomnia drug on the brink of approval nod

by Osborne, Randy
Published in Nature reviews. Drug discovery (01.07.2013)

Get full text

Journal Article

Synthetic peptide allergy vaccine shows efficacy

Synthetic peptide allergy vaccine shows efficacy

by Osborne, Randy
Published in Nature biotechnology (01.05.2013)

Get full text

Journal Article

First-in-class insomnia drug on the brink of approval nod: Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered

First-in-class insomnia drug on the brink of approval nod: Merck's dual orexin receptor antagonist suvorexant is approaching the regulatory finish line, 15 years after orexins were discovered

by Osborne, Randy
Published in Nature reviews. Drug discovery (01.07.2013)

Get full text

Journal Article

Fresh from the biotech pipeline--2012: FDA approvals hit a new high mark in 2012, with a December flurry of approvals. Orphan and fast-track drugs showed strong in the list Randy Osborne reports

Fresh from the biotech pipeline--2012: FDA approvals hit a new high mark in 2012, with a December flurry of approvals. Orphan and fast-track drugs showed strong in the list Randy Osborne reports

by Osborne, Randy
Published in Nature biotechnology (01.02.2013)

Get full text

Journal Article

Commercial interest waxes for IGF-1 blockers

Commercial interest waxes for IGF-1 blockers

by Osborne, Randy
Published in Nature biotechnology (01.07.2008)

Get full text

Journal Article

Constellation pharmaceuticals: replete with investor funds, the Cambridge, Massachusetts--based epigenetics firm is taking aim at methylases and demethylases linked to disease

Constellation pharmaceuticals: replete with investor funds, the Cambridge, Massachusetts--based epigenetics firm is taking aim at methylases and demethylases linked to disease

by Osborne, Randy
Published in Nature biotechnology (01.10.2010)

Get full text

Journal Article

Newsmaker: Constellation Pharmaceuticals

Newsmaker: Constellation Pharmaceuticals

by Osborne, Randy
Published in Nature biotechnology (01.10.2010)

Get full text

Journal Article

Brand biologics grab 12 years' exclusivity, for now

by Osborne, Randy
Published in Nature biotechnology (01.08.2009)

Get full text

Journal Article

The lengthening handshake

The lengthening handshake

by Osborne, Randy
Published in Nature biotechnology (01.03.2010)

Get full text

Journal Article

The lengthening handshake: although mergers and acquisitions

The lengthening handshake: although mergers and acquisitions

by Osborne, Randy
Published in Nature biotechnology (01.03.2010)

Get full text

Journal Article

The lengthening handshake: although mergers and acquisitions (MAs) failed to hit the heights some analysts had predicted in 2009, a new type of tiered transaction rose to prominence--the structured deal. Randy Osborne reports

The lengthening handshake: although mergers and acquisitions (MAs) failed to hit the heights some analysts had predicted in 2009, a new type of tiered transaction rose to prominence--the structured deal. Randy Osborne reports

by Osborne, Randy
Published in Nature biotechnology (01.03.2010)

Get full text

Journal Article

Ark floats gene therapy's boat, for now

Ark floats gene therapy's boat, for now

by Osborne, Randy
Published in Nature biotechnology (01.10.2008)

Get full text

Journal Article

US regulator wades into stem cell therapies for heart disease

US regulator wades into stem cell therapies for heart disease

by Osborne, Randy
Published in Nature biotechnology (01.06.2009)

Get full text

Journal Article

Buzz around Campath proof-of-concept trial in MS

Buzz around Campath proof-of-concept trial in MS

by Osborne, Randy
Published in Nature biotechnology (01.01.2009)

Get full text

Journal Article

FDA on warpath for Google links

FDA on warpath for Google links

by Osborne, Randy
Published in Nature biotechnology (01.05.2009)

Get full text

Journal Article

FDA and surrogate endpoints in Alzheimer's disease

FDA and surrogate endpoints in Alzheimer's disease

by Osborne, Randy
Published in Nature biotechnology (01.08.2008)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
11
Next
[20]